Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2022 · 10-Q
Revenue$8.19M$8.19M+1.6% vs Q3 2021 Net Income-$14.21M-$14.21MN/M vs Q3 2021 EPS Diluted-$3.35-$3.35N/M vs Q3 2021 Gross Profit$4,732,000+6.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,244,000N/M Free Cash Flowderived-$3,284,000N/M Margins · derivedGross margin57.8%+2.7 pt vs Q3 2021
Operating margin-9.5%+13.1 pt vs Q3 2021
Net margin-173.5%−129.3 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end